1. Home
  2. DMAC vs GPRK Comparison

DMAC vs GPRK Comparison

Compare DMAC & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$6.58

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Logo Geopark Ltd

GPRK

Geopark Ltd

HOLD

Current Price

$9.14

Market Cap

608.0M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMAC
GPRK
Founded
2000
2002
Country
United States
Colombia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
428.6M
608.0M
IPO Year
2018
2009

Fundamental Metrics

Financial Performance
Metric
DMAC
GPRK
Price
$6.58
$9.14
Analyst Decision
Strong Buy
Hold
Analyst Count
4
1
Target Price
$15.50
$8.50
AVG Volume (30 Days)
214.6K
1.4M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
1.21%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$500,000.00
N/A
Revenue This Year
N/A
$39.45
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$12.70
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$5.75
52 Week High
$10.42
$10.34

Technical Indicators

Market Signals
Indicator
DMAC
GPRK
Relative Strength Index (RSI) 44.64 51.37
Support Level $6.56 $7.96
Resistance Level $7.36 $10.16
Average True Range (ATR) 0.48 0.57
MACD 0.04 0.01
Stochastic Oscillator 50.00 55.10

Price Performance

Historical Comparison
DMAC
GPRK

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About GPRK Geopark Ltd

GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.

Share on Social Networks: